# To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

> **NCT03658213** · PHASE3 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ZOLADEX 10.8 mg
- **DRUG:** ZOLADEX 3.6mg

## Key facts

- **NCT ID:** NCT03658213
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-31
- **Primary completion:** 2021-11-04
- **Final completion:** 2021-11-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** CTP of LARES has been out of the expire date, we are trying RWS pathway for the indication expend
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03658213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03658213, "To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03658213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*